2 Day Conference: Next-Gen Regenerative Medicine & Tissue Engineering - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 20, 2018--The “Next-Gen Regenerative Medicine & Tissue Engineering Conference” conference has been added to ResearchAndMarkets.com’s offering.
Ethical and regulatory parameters lay a special emphasis on animal modeling to carry forward the researches over tissue engineering and organ transplantation. This is one of the major challenge being faced for the clinical applications of regenerative medicine.
The translational research promises to improvise a structural shift in healthcare by focusing on the underlying causes of disease by repairing, replacing, or regenerating damaged cells in the body. The conference aims on these similar lines to assess risks and benefits of regenerative medicine through the application of cellular therapies, stem cells and biocompatible materials.
The event provider has put together a platform for the leading experts of industry to discuss strategies, technologies and innovations in tissue engineering & biomaterials, cellular therapies and diagnosis of regenerative medicines at the Next-Gen Regenerative Medicine & Tissue Engineering Conference.
Key HighlightsCell based tissue engineering Tissue-specific biomarkers Tissue scaffolding Cell surface profiling Processing of iPSC cells iPSC derived mesenchymal cells T-cell identification and regulation Regulatory and ethical issues of regenerative medicines Genetic models for neurodegenerative disorders Organ transplantation and regeneration
Francisco Vidal Fayos Director, Aastrom Biosciences
Dr. Tiffany Rau Senior Consultant, Bioprocessing Technology Consultants
Alain Vertes Managing Director, NxR Biotechnlogies GMBH
Alain Vertes Managing Director, NxR Biotechnlogies GMBH, Switzerland
Wilfred T.V. Germeraad Chief Scientific Officer, CiMaas BV, Netherlands
Philippe Henon President & Chief Scientific Officer, CellProthera, France
Roland Klar Head of Regenerative Medicine, Ludwig Maximilian University of Munich, Germany
Yang (Ted) D. Teng Ph.D., M.D., Departments of Physical Medicine & Rehabilitation (PM&R) & Neurosurgery, Harvard Medical School, Boston, MA, USA
Suwan N. Jayasinghe Professor, Bioengineering, University College London, UK
James Adjaye Chair of Stem Cell Research & Regenerative Medicine, Director, Institute for Stem Cell Research & Regenerative Medicine, Germany
Alexander Seflian Director & Professor of Nanotechnology & Regenerative Medicine, The London BioScience Innovation Center,UK
Antonio Apicella Researcher, University of Campania, Italy
Roland Hetzer Cardiac Surgeon, Germany
Oliver Betz Director, Regenerative Medicine, Ludwig-Maximilians -University, of Munich, Germany
Tiffany Rau Senior Consultant, Bioprocessing Technology Consultants, USA
David Gilham Vice President, Research & Development, Celyad, Belgium
For more information about this conference visit https://www.researchandmarkets.com/research/d3jjs6/2_day_conference?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180820005253/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Biopharmaceuticals ,Biomaterials
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/20/2018 07:35 AM/DISC: 08/20/2018 07:35 AM